Why Turn Therapeutics Inc.’s (TTRX) Stock Is Up 6.23%
As of Wednesday, October 14, Turn Therapeutics Inc.’s TTRX share price has surged by 6.23%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.
Commentary & Analysis
Why Turn Therapeutics Inc.’s (TTRX) Stock Is Down 6.12%
As of Thursday, October 08, Turn Therapeutics Inc.’s TTRX share price has dipped by 6.12%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Turn Therapeutics Inc.’s (TTRX) Stock Is Up 7.65%
As of Wednesday, October 07, Turn Therapeutics Inc.’s TTRX share price has surged by 7.65%, which has investors questioning if this is right time to sell.Michael Rose
Why Turn Therapeutics Inc.’s (TTRX) Stock Is Up 11.17%
As of Wednesday, October 07, Turn Therapeutics Inc.’s TTRX share price has surged by 11.17%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Turn Therapeutics Inc.’s (TTRX) Stock Is Down 8.33%
As of Monday, October 05, Turn Therapeutics Inc.’s TTRX share price has dipped by 8.33%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | TTRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $306.2 | $464.0 | 33% |
|
| Shares Out (Mil) | 29.8 | 42.7 | 37% |
|
| Institutional Ownership | 6.3% | 82.2% | 5% |
|
| Float (Mil) | 10.8 | 44.3 | 20% |
|
| Beta | na | 0.73 | na |
|
| Avg Daily Volume (000s) | 77 | 292 | 34% |
|
| Price Change (52-week) |
145.9% | 55.0% | 98% |
|
| Growth | TTRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.4%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TTRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($11) | 30% |
|
| EPS (TTM) | ($0.292) | ($0.700) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($7) | 26% |
|
| Net Cash Flow (TTM) (Mil) | $7 | $5 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $6 | 26% |
|
| Enterprise Value (Q1) (Mil) | $384 | $493 | 32% |
|
| Valuation | TTRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 514.00 | 2.09 | 100% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | TTRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (79.3%) | (22.2%) | 7% |
|
| ROE | (686.3%) | (21.0%) | 1% |
|
| Liabilities to Assets | 96.0% | 32.3% | 93% |
|
| F-Score | 2 | 3 | 7% |
|
Turn Therapeutics Inc. did not pass any screens on 10/23/2026.
